araag2/HINT huggingface dataset:
Clinical trial NCT00256854 (phase 3, status: completed)
Conditions: restless legs syndrome, restless legs syndrome (rls)
ICD codes: G25.81, G25.81, R45.1
Drugs: ropinirole ir 1 mg, ropinirole ir 2 mg, ropinirole ir 1 mg placebo, ropinirole ir 2 mg placebo, ropinirole cr 2 mg, ropinirole cr 3 mg, ropinirole cr 2 mg placebo, ropinirole cr 3 mg placebo
SMILES: CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1, CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1, CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1, CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1, CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1, CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1, CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1, CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of RLS using IRLS Study Group (IRLSSG) diagnostic criteria.

          -  Subjects currently being treated for RLS with a stable dose (for at least 2 weeks) of
             ropinirole IR given once daily.

          -  Subjects with RLS symptoms during both the evening and night or night time only.

          -  Subjects who have given written informed consent to participate.

        Exclusion Criteria:

          -  Subjects who require treatment of daytime RLS symptoms.

          -  Signs of secondary RLS, serum ferritin level less than 10 mcg/L.

          -  Movement Disorders, Clinically significant or unstable medical conditions.

          -  Abnormal labs, electrocardiogram (ECG) or physical findings.

          -  Receiving prohibited medications.

          -  Sleeping habits incompatible with study design.

          -  Intolerance to ropinirole or other dopamine agonist.

          -  Pregnant or lactating.

          -  Women of child-bearing potential who are not practicing an acceptable method of birth
             control.
Clinical trial NCT00372216 (phase 3, status: completed)
Conditions: myocardial infarction
ICD codes: I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8
Drugs: clopidogrel (iscover/plavix)
SMILES: [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Acute STEMI <= 6 hrs.

          -  Planned percutaneous coronary intervention

          -  Age >= 18 years

          -  Ability to understand the natures, scope, and possible consequences of the study /
             legal capacity

          -  Informed consent

        Exclusion Criteria:

          -  Thrombolytic therapy within 24 hours before randomization

          -  Effective oral or intravenous anticoagulation (INR>2, or PTT>2xcontrol)

          -  Known hemorrhagic diathesis

          -  Stroke or TIA within 3 months

          -  Evidence of an active gastrointestinal or urogenital bleeding

          -  Major surgery (including CABG) within 6 weeks

          -  Contraindication to Clopidogrel

          -  Severe renal or hepatic insufficiency

          -  Contraindication to coronary angiography

          -  Planned administration of a GP IIb/IIIa-Inhibitor before angiography

          -  Pregnant or nursing (lactating) women

          -  Women with childbearing potential

          -  Patients currently (within the last 10 days) treated with clopidogrel or ticlopidine

          -  Participation in another clinical or device trial within the previous 30 days
Clinical trial NCT00003652 (phase 3, status: completed)
Conditions: anal cancer
ICD codes: C21.1, C44.500, C44.590, D12.9, C21.8
Drugs: cisplatin, fluorouracil
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically proven nonmetastatic anal cancer

               -  Anal/rectal junction OR

               -  Anal/cutaneous junction with the majority of the tumor in the anal canal, above
                  the junction

               -  Epidermoid cancer (well-differentiated, fairly differentiated, or basaloid) OR

               -  Cloacogenic cancer

               -  Stage II or III

                    -  T2 at least 4 cm OR

                    -  T3 OR

                    -  T4, N0-3, M0 OR

                    -  T1, N1-3 OR

                    -  T2 (less than 4 cm), N1-3

          -  Tumors at least 4 cm in greatest dimension and/or tumors with lymph node invasion must
             be nonmetastatic by ultrasound

          -  No prior surgery to remove tumor

        PATIENT CHARACTERISTICS:

        Age:

          -  80 and under

        Performance status:

          -  WHO 0 or 1

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 2,000/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin at least 11 g/dL (transfusion allowed)

        Hepatic:

          -  Not specified

        Renal:

          -  Creatinine no greater than 1.5 mg/dL

        Cardiovascular:

          -  No cardiac condition contraindicating use of fluorouracil

        Other:

          -  No prior malignancy within 5 years except squamous cell or basal cell skin cancer or
             carcinoma in situ of the cervix or breast

          -  No other serious medical or psychological condition

          -  No serious immunosuppression

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior biologic therapy

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  No prior endocrine therapy

        Radiotherapy:

          -  No prior pelvic or inguinal radiotherapy

        Surgery:

          -  See Disease Characteristics

          -  No prior definitive colostomy
Clinical trial NCT00275652 (phase 3, status: completed)
Conditions: hepatitis b, cirrhosis
ICD codes: B18.0, B18.1, B19.10, B19.11, B17.0, B16.0, B16.1, K74.3, K74.4, K74.5, K74.60, K74.69, P78.81, K70.30
Drugs: ldt (telbivudine) and lamivudine
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1CS[C@H](CO)O1
Eligibility criteria:

        Patients with chronic hepatitis b with evidence of cirrhosis, who are at least 18 to 70
        years old, may be eligible to participate in this study.
Clinical trial NCT01286935 (phase 3, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: safinamide, safinamide, placebo
SMILES: C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O, C[C@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  The patient completed 24 weeks of treatment in Study 016, or, if the patient
             discontinued prematurely, he/she returned for scheduled efficacy evaluations at Weeks
             12 and 24, as part of the Retrieved Dropout (RDO) population.

          -  The patient was compliant with taking study medication in Study 016.

          -  The patient is willing to participate in the study and signed an approved Informed
             Consent form.

        Exclusion Criteria:

          -  The patient is experiencing clinically significant adverse events that would put the
             patient at risk for participating in the study.

          -  The patient has shown clinically significant deterioration during participation in
             Study 016, and has reached Hoehn and Yahr Stage V.

          -  The patient discontinued Study 016 prematurely for any reason, and did not return for
             scheduled efficacy evaluations at Weeks 12 and 24.
Clinical trial NCT00444873 (phase 3, status: completed)
Conditions: acromegaly
ICD codes: E22.0
Drugs: lanreotide (autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
SMILES: [H]N([H])CCCCC1N([H])C(=O)C(CC2=CN([H])C3=CC=CC=C23)N([H])C(=O)C(CC2=CC=C(O)C=C2)N([H])C(=O)C(CSSCC(N([H])C(=O)C(N([H])C1=O)C(C)C)C(=O)N([H])C(C(C)O)C(=O)N([H])[H])N([H])C(=O)C(CC1=CC2=CC=CC=C2C=C1)N([H])[H]
Eligibility criteria:

        Inclusion Criteria:

          -  The patient must give written (personally signed and dated) informed consent before
             completing any study-related procedure.

          -  The patient must have a documented diagnosis of active acromegaly and be adequately
             treated with a stable dose (10, 20 or 30 mg) of Octreotide LAR for at least 6 months
             immediately prior to study entry. A documented diagnosis of active acromegaly is
             defined as IGF-1 more than 30% higher than two Standard Deviations ( +2 SD) above the
             normal age and sex adjusted value (see Appendix 6) or GH level after OGTT (Oral
             Glucose Tolerance Test) > 2ng/mL while not under drug treatment for acromegaly. For
             patients having undergone surgery or radiotherapy, this diagnosis must have been
             performed after the most recent surgical or radiation treatment

        Exclusion Criteria:

          -  The patient has had pituitary surgery (adenomectomy) within 6 months prior to study
             entry

          -  The patient has received stereotactic (LINAC, Gamma Knife) radiotherapy for acromegaly
             within three years or conventional radiotherapy for acromegaly within five years prior
             to study entry
Clinical trial NCT00596466 (phase 3, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: pregabalin
SMILES: NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Completed the previous protocol and wish to continue to receive pregabalin.

          -  Diagnosis of epilepsy with partial seizures

        Exclusion Criteria:

          -  Early withdrawal from the previous protocol, an episode of status epliepticus, or
             primary generalized epilepsy.
Clinical trial NCT00312377 (phase 3, status: completed)
Conditions: non-small cell lung cancer, lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: docetaxel, vandetanib
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC
Eligibility criteria:

        Inclusion Criteria:

        Lung cancer patients who answer true to the following statements are eligible to join this
        clinical study.

          -  I have a confirmed diagnosis of locally advanced or metastatic non small cell lung
             cancer (Stage IIIb - IV)

          -  I have had 1st line anti-cancer therapy. Previous treatment with Avastin (bevacizumab)
             in first line NSCLC is allowed.

        Exclusion Criteria:

        Lung cancer patients who answer true to the following are NOT eligible to join this
        clinical study.

          -  I do not have non small cell lung cancer (NSCLC)

          -  I have received treatment with docetaxel (Taxotere). Prior treatment with paclitaxel
             is acceptable.

          -  I have received 2nd line anti-cancer therapy (For example, patients with previous 2nd
             line non small cell lung cancer (NSCLC) treatment with Tarceva (erlotinib, OSI-744),
             Alimta (pemetrexed) are not eligible)

          -  I have been treated with VEGFR-tyrosine kinase inhibitors (TKIs) (sunitinib,
             sorafenib, other VEGF TKIs). Previous treatment with Avastin (bevacizumab) in 1st line
             non small cell lung cancer is permitted.

          -  I have a history of uncontrolled irregular heartbeat

          -  I have a history of high blood pressure which has not been controlled with medication
             If you are unsure of the meaning of the inclusion and exclusion criteria above, please
             contact the call center number for help.
Clinical trial NCT00454584 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: cnto 1275 45 mg, cnto 1275 90 mg, etanercept 50 mg
SMILES: O
Eligibility criteria:

        Inclusion Criteria:

          -  Have had a diagnosis of plaque-type psoriasis at least 6 months prior to the study

          -  Have plaque-type psoriasis covering at least 10 percentage of total body surface area

          -  Have a Psoriasis Area and Severity Index (PASI) score of 12 or greater and a
             Physician's Global Assessment (PGA) score of 3 or greater at the time of the first
             administration of study drug

          -  Must be suitable for phototherapy or systemic treatment for psoriasis

          -  Have failed to respond to or have condition which prevents use of cyclosporine,
             methotrexate (MTX) or psoralen plus ultraviolet light A (PUVA)

        Exclusion Criteria:

          -  Currently have nonplaque forms of psoriasis

          -  Have current drug-induced psoriasis

          -  Have used any therapeutic agent targeted at reducing interleukin-12 (IL-12) or IL-23
             (Interleukins are the substance produced by body in immunological disease like
             psoriasis)

          -  Have received phototherapy or any systemic medications/treatments that could affect
             psoriasis or PASI evaluation (including, but not limited to, oral or injectable
             corticosteroids, retinoids, 1,25 dihydroxy vitamin D3 and analogues, psoralens,
             sulfasalazine, hydroxyurea, or fumaric acid derivatives) within 4 weeks of the first
             administration of study agent

          -  Have used a biologic within the previous 3 months
Clinical trial NCT00092989 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: montelukast sodium, placebo
SMILES: [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Individuals with acute asthma

        Exclusion Criteria:

          -  Women of child bearing age

          -  History of Chronic Obstructive Pulmonary Disease (COPD)
Clinical trial NCT01157078 (phase 3, status: completed)
Conditions: major depressive disorder, depression
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40, F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: tc-5214, placebo
SMILES: CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of signed and dated informed consent before initiation of any study-related
             procedures.

          -  The patient must have a clinical diagnosis of major depressive disorder (MDD) with
             inadequate response to no more than one antidepressant.

          -  Out-patient status at enrollment and randomization.

        Exclusion Criteria:

          -  Patients with a lifetime history of bipolar disorder, psychotic disorder or
             post-traumatic stress disorder.

          -  Patients with a history of suicide attempts in the past year and/or seen by the
             investigator as having a significant history of risk of suicide or homicide.

          -  History of renal insufficiency or impairment or conditions that could affect
             absorption or metabolism of the investigational product in this patient population
Clinical trial NCT00461617 (phase 3, status: completed)
Conditions: diabetes
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65
Drugs: mitiglinide
SMILES: [H][C@@](CC(=O)N1C[C@@]2([H])CCCC[C@@]2([H])C1)(CC1=CC=CC=C1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes patients with inadequate control of blood glucose with diet and/or
             exercise therapy

        Exclusion Criteria:

          -  Type 1 diabetes patients

          -  Patients who require treatment with insulin

          -  Patients with severe diabetic complications (neuropathy, retinopathy or nephropathy)

          -  Patients with severe ketosis, diabetic coma or precoma

          -  Patients complicated with severe hepatic diseases

          -  Patients complicated with severe renal diseases

          -  Patients complicated with severe hypertension

          -  Patients complicated with severe cardiac disease

          -  Pregnant women or women possible to be pregnant, nursing women, or women who want to
             become pregnant during the study period
Clinical trial NCT01724528 (phase 3, status: completed)
Conditions: tumor lysis syndrome
ICD codes: E88.3
Drugs: febuxostat, allopurinol
SMILES: CC(C)COC1=C(C=C(C=C1)C1=NC(C)=C(S1)C(O)=O)C#N, O=C1N=CN=C2NNC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Patients scheduled for first cytotoxic chemotherapy cycle, regardless of the line of
             treatment, because of hematologic malignancies at intermediate or high risk of TLS
             (according to the TLS risk stratification, Cairo M et al, British Journal of
             Haematology, 2010)candidate to Allopurinol treatment or have no access to Rasburicase

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3

          -  Life expectancy > 1 month

        Exclusion Criteria:

          -  Patients known to be hypersensitive to Febuxostat or Allopurinol or to any of the
             components of the formulations

          -  Patients with sUA levels ≥ 10 mg/dL at randomization

          -  Patients receiving Febuxostat, Allopurinol or any other urate lowering therapy (e.g.
             Rasburicase, probenecid) within 30 days prior to randomization

          -  Patients with severe renal and/or hepatic insufficiency

          -  Patients with diagnosis of LTLS or CTLS at randomization
Clinical trial NCT01743729 (phase 3, status: completed)
Conditions: dry eye disease
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: lifitegrast, placebo
SMILES: CS(=O)(=O)C1=CC(C[C@H](NC(=O)C2=C(Cl)C3=C(CN(CC3)C(=O)C3=CC=C4C=COC4=C3)C=C2Cl)C(O)=O)=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Willing and able to read, sign and date the informed consent and HIPAA documents

          -  Willing and able to comply with all study procedures

          -  Be at least 18 years of age

          -  Patient-reported history of dry eye in both eyes

          -  A negative urine pregnancy test if female of childbearing potential and must use
             adequate birth control throughout the study period

          -  Artificial tear use within the past 30 days

        Exclusion Criteria:

          -  Any ocular condition that, in the opinion of the Investigator, could affect study
             parameters including, but not limited to, active ocular infection, ocular
             inflammation, glaucoma, and/or diabetic retinopathy

          -  Unwilling to avoid wearing contact lenses for 7 days prior to first visit and for the
             duration of the study

          -  Any blood donation or significant loss of blood within 56 days of Visit 1

          -  Any history of immunodeficiency disorder, positive HIV, hepatitis B, C, or evidence of
             acute active hepatitis A (anti-HAV IgM), or organ or bone marrow transplant.

          -  Use of any prohibited medications at any time during the study unless otherwise
             specified

          -  Any significant illness that could interfere with study parameters

          -  History of laser assisted in situ keratomileusis (LASIK) or similar type of corneal
             refractive surgery within 12 months prior to first visit, and/or any other ocular
             surgical procedure within 12 months prior to first visit; or any scheduled ocular
             surgical procedure during the study period.

          -  Known history of alcohol and/or drug abuse

          -  Subjects with Dry eye secondary to scarring or destruction of conjunctival goblet
             cells (as with Vitamin A deficiency)
Clinical trial NCT00658788 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: clobetasol propionate spray 0.05%, calcitriol ointment
SMILES: [H][C@@]12C[C@H](C)[C@](OC(=O)CC)(C(=O)CCl)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of moderate to severe plaque psoriasis, defined as 3% - 20% treatable body
             surface area

          -  Overall Disease Severity of at least 3 (moderate)

        Exclusion Criteria:

          -  Surface area involvement too large (>20% BSA)

          -  Psoriasis involving only the scalp, groin, axillae, and/or other intertriginous areas
Clinical trial NCT00261326 (phase 3, status: unknown status)
Conditions: optic neuritis, multiple sclerosis
ICD codes: H46.8, H46.9, G35, C81.18
Drugs: simvastatin, placebo
SMILES: CC1=CC(O)=CC(C)=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Acute Optic Neuritis

          -  Abnormal contrast sensitivity score (>80)

          -  Symptom duration maximum 4 weeks

          -  Men and women between 18 and 59 years old

          -  The patient must be physical and mental able to participate i this project with a 6
             months of the duration

          -  The patient must sign the written consent of the participation before the inclusion.

        Exclusion Criteria:

          -  Optic neuritis earlier in the same eye

          -  Pregnancy

          -  Nursing

          -  Fertile women who do not use contraception

          -  Women who contemplate pregnancy in the duration of the study

          -  Steroid treatment the last 4 weeks before the inclusion

          -  Immune-supressor treatment the last 6 months before the inclusion

          -  Active liver disease or continuous increase of liver enzymes (ASAT, ALAT)without known
             reason.

          -  Kidney failure

          -  Myopathy

          -  Hyperthyroidism

          -  Diabetes mellitus

          -  Alcoholism

          -  Fibrates intake

          -  Statin treatment for other disease

          -  Simultaneous participation in other studies.
Clinical trial NCT00273299 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: valsartan plus hydrochlorothiazide
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed severe hypertension

        Exclusion Criteria:

          -  Inability to discontinue all prior antihypertensive medications

          -  Heart failure of any kind

          -  History of stroke, transient ischemic attack, myocardial infarction, chest pain,
             abnormal heart rhythm Liver, kidney, or pancreas disease

          -  Diabetes with poor glucose control

          -  Allergy to certain medications used to treat high blood pressure

        Other protocol-defined exclusion criteria may apply.